Access to care among patients with osteogenesis imperfecta during the COVID-19 pandemic.


Journal

Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 15 08 2023
accepted: 17 11 2023
medline: 29 11 2023
pubmed: 28 11 2023
entrez: 28 11 2023
Statut: epublish

Résumé

In a cross-sectional study assessing the experiences of individuals with osteogenesis imperfecta accessing care during the COVID-19 pandemic, participants reported high rates of delays in accessing medical care and high utilization of telehealth. Considering the needs of individuals with complex medical conditions is important when improving access to care. Individuals with osteogenesis imperfecta (OI) often have complex care needs requiring that they see a variety of specialists. The onset of the COVID-19 pandemic in March 2020 led to delays in medical care for many health conditions. The goal of this study was to describe the experiences of individuals with OI accessing medical care during this time. Responses to an electronic survey distributed via the OI Foundation mailing list were collected from August 2020 until February 2021. Participants were instructed to compare their experiences in the months since the start of the pandemic with their experiences prior to this date. Data were analyzed using descriptive statistics and were compared across demographic groups using logistic regression and chi-squared tests. Surveys were completed by 110 participants. Most participants (72%) reported experiencing delays in accessing at least one care provider. The majority of participants reported less or similar amounts of bone pain (74.3%) and less or the same rate of fracture (88.6%) as before the start of the pandemic. While most study participants experienced delays in care, they did not report an increase in symptoms associated with OI. They also frequently utilized telehealth as a tool to see their providers. Future research should focus on the impact of changes in telehealth legislation on patients' ability to access care. As methods for care delivery evolve, the needs of people with OI and other rare diseases should be considered and prioritized.

Identifiants

pubmed: 38015270
doi: 10.1007/s11657-023-01355-2
pii: 10.1007/s11657-023-01355-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

143

Subventions

Organisme : NCATS NIH HHS
ID : TL1 TR002382
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR002378
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1TR002382
Pays : United States

Informations de copyright

© 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.

Références

Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. The Lancet 363(9418):1377–1385. https://doi.org/10.1016/S0140-6736(04)16051-0
doi: 10.1016/S0140-6736(04)16051-0
Tournis S, Dede AD (2018) Osteogenesis imperfecta–a clinical update. Metabolism 80:27–37. https://doi.org/10.1016/j.metabol.2017.06.001
doi: 10.1016/j.metabol.2017.06.001 pubmed: 28625337
Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16(2):101. https://doi.org/10.1136/jmg.16.2.101
doi: 10.1136/jmg.16.2.101 pubmed: 458828 pmcid: 1012733
Osteogenesis Imperfecta (OI) (2023).  https://my.clevelandclinic.org/health/diseases/15807-osteogenesis-imperfecta-oi . Accessed 4 Aug 2023
Hidalgo Perea S, Green DW (2021) Osteogenesis imperfecta: treatment and surgical management. Curr Opin Pediatr 33(1):74–48. https://doi.org/10.1097/MOP.0000000000000968
doi: 10.1097/MOP.0000000000000968 pubmed: 33278111
Aktas P (2021) Chronic and rare disease patients’ access to healthcare services during a health crisis: the example of the COVID-19 pandemic in Turkey. Health Expect 24(5):1812–1820. https://doi.org/10.1111/hex.13321
doi: 10.1111/hex.13321 pubmed: 34309998 pmcid: 8444723
Papautsky EL, Rice DR, Ghoneima H, McKowen ALW, Anderson N, Wootton AR et al (2021) Characterizing health care delays and interruptions in the United States during the COVID-19 pandemic: internet-based, cross-sectional survey study. J Med Internet Res 23(5):e25446. https://doi.org/10.2196/25446
doi: 10.2196/25446 pubmed: 33886489 pmcid: 8136407
Soussand L, Kuchenbuch M, Messiaen C, Sandrin A, Jannot AS, Nabbout R (2022) Impact of the COVID-19 pandemic on the care of rare and undiagnosed diseases patients in France: a longitudinal population-based study. Orphanet J Rare Dis 17(1):430. https://doi.org/10.1186/s13023-022-02580-7
doi: 10.1186/s13023-022-02580-7 pubmed: 36494730 pmcid: 9733228
Sokas C, Kelly M, Sheu C, Song J, Welch HG, Bergmark R et al (2021) Cancer in the shadow of COVID: early-stage breast and prostate cancer patient perspectives on surgical delays due to COVID-19. Ann Surg Oncol 28(13):8688–8696. https://doi.org/10.1245/s10434-021-10319-0
doi: 10.1245/s10434-021-10319-0 pubmed: 34170430 pmcid: 8231084
De Luca P, Bisogno A, Colacurcio V, Marra P, Cassandro C, Camaioni A et al (2022) Diagnosis and treatment delay of head and neck cancers during COVID-19 era in a tertiary care academic hospital: what should we expect? Eur Arch Otorhinolaryngol 279(2):961–965. https://doi.org/10.1007/s00405-021-06834-1
doi: 10.1007/s00405-021-06834-1 pubmed: 33929609
Lee DID, Vanderhout S, Aglipay M, Birken CS, Morris SK, Piché-Renaud PP et al (2022) Delay in childhood vaccinations during the COVID-19 pandemic. Can J Public Health 113(1):126–134. https://doi.org/10.17269/s41997-021-00601-9
doi: 10.17269/s41997-021-00601-9 pubmed: 35060107 pmcid: 8773389
Nutt S, Limb L (2011) Survey of patients’ and families’ experiences of rare diseases reinforces calls for a rare disease strategy. Soc Care Neurodisability 2(4):195–199. https://doi.org/10.1108/20420911111188443
doi: 10.1108/20420911111188443
Halley MC, Stanley T, Maturi J, Goldenberg AJ, Bernstein JA, Wheeler MT et al (2021) “It seems like COVID-19 now is the only disease present on Earth”: living with a rare or undiagnosed disease during the COVID-19 pandemic. Genet Med 23(5):837–844. https://doi.org/10.1038/s41436-020-01069-7
doi: 10.1038/s41436-020-01069-7 pubmed: 33420343 pmcid: 7792915
Smyth D, Hytiris M, Kelday C, McDonnell C, Burren C, Gardner A et al (2022) Patient-reported experience of clinical care of osteogenesis imperfecta (OI) during the COVID-19 pandemic. Front Public Health 10:951569. https://doi.org/10.3389/fpubh.2022.951569
doi: 10.3389/fpubh.2022.951569 pubmed: 36684962
Findling MG, Blendon RJ, Benson JM (2020) Delayed care with harmful health consequences—reported experiences from national surveys during coronavirus disease 2019. JAMA Health Forum 1(12):e201463-e. https://doi.org/10.1001/jamahealthforum.2020.1463
doi: 10.1001/jamahealthforum.2020.1463
Atherly A, Van Den Broek-Altenburg E, Hart V, Gleason K, Carney J (2020) Consumer reported care deferrals due to the COVID-19 pandemic, and the role and potential of telemedicine: cross-sectional analysis. JMIR Public Health Surveill 6(3):e21607. https://doi.org/10.2196/21607
doi: 10.2196/21607 pubmed: 32833661 pmcid: 7498465
About OI (2023).  https://oif.org/informationcenter/about-oi/ . Accessed 1 Aug 2023
Swezey T, Reeve BB, Hart TS, Floor MK, Dollar CM, Gillies AP et al (2019) Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community. Osteoporos Int 30(2):507–511. https://doi.org/10.1007/s00198-018-4690-7
doi: 10.1007/s00198-018-4690-7 pubmed: 30191258
Mc Donald D, Mc Donnell T, Martin-Grace J, Mc Manus G, Crowley RK (2023) Systematic review of health related-quality of life in adults with osteogenesis imperfecta. Orphanet J Rare Dis 18(1):36. https://doi.org/10.1186/s13023-023-02643-3
doi: 10.1186/s13023-023-02643-3 pubmed: 36814291 pmcid: 9945612
United States Regions (2023). https://education.nationalgeographic.org/resource/united-states-regions/ . Accessed 1 Aug 2023

Auteurs

Sara N Malina (SN)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Johns Hopkins University School of Medicine, 200 N. Wolfe St., Suite 3120, Baltimore, MD, 21287, USA.

Jill C Flanagan (JC)

Children's Physician Group-Orthopedics and Sports Medicine at Children's Healthcare of Atlanta, Atlanta, GA, USA.

Karen J Loechner (KJ)

Division of Pediatric Endocrinology and Children's Healthcare of Atlanta Pediatric Bone Clinic, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Division of Pediatric Endocrinology, Department of Pediatrics, Connecticut Children's Hospital, Hartford, CT, USA.

Malinda Wu (M)

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Johns Hopkins University School of Medicine, 200 N. Wolfe St., Suite 3120, Baltimore, MD, 21287, USA. mwu86@jhmi.edu.
Division of Pediatric Endocrinology and Children's Healthcare of Atlanta Pediatric Bone Clinic, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. mwu86@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH